Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1139

1.

Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.

Felker GM, Hasselblad V, Hernandez AF, O'Connor CM.

Am Heart J. 2009 Sep;158(3):422-30. doi: 10.1016/j.ahj.2009.06.018. Epub 2009 Jul 9.

PMID:
19699866
2.

B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.

Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H.

Arch Intern Med. 2010 Mar 22;170(6):507-14. doi: 10.1001/archinternmed.2010.35.

PMID:
20308637
3.

Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure.

Miller WL, Hartman KA, Grill DE, Burnett JC Jr, Jaffe AS.

Clin Chem. 2009 Jan;55(1):78-84. doi: 10.1373/clinchem.2008.108928. Epub 2008 Nov 21.

4.

Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure.

Clerico A, Fontana M, Ripoli A, Emdin M.

Adv Clin Chem. 2009;48:163-79.

PMID:
19803419
5.

B-type natriuretic peptide in heart failure.

Moe GW.

Curr Opin Cardiol. 2006 May;21(3):208-14. Review.

PMID:
16601459
6.

B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.

De Vecchis R, Esposito C, Di Biase G, Ariano C, Giasi A, Cioppa C.

J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):122-34. doi: 10.2459/JCM.0b013e328364bde1. Review.

PMID:
24522083
7.

N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.

Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R.

J Am Coll Cardiol. 2010 Feb 16;55(7):645-53. doi: 10.1016/j.jacc.2009.08.078.

8.

N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.

Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM.

J Am Coll Cardiol. 2009 Dec 29;55(1):53-60. doi: 10.1016/j.jacc.2009.02.095.

9.

N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome.

Rutten JH, Steyerberg EW, Boomsma F, van Saase JL, Deckers JW, Hoogsteden HC, Lindemans J, van den Meiracker AH.

Am Heart J. 2008 Jul;156(1):71-7. doi: 10.1016/j.ahj.2008.02.021. Epub 2008 May 27.

PMID:
18585499
10.

Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.

Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, Leosco D, Perrone-Filardi P.

PLoS One. 2013;8(3):e58287. doi: 10.1371/journal.pone.0058287. Epub 2013 Mar 5. Erratum in: PLoS One. 2014;9(4):e96706.

11.

The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use.

Januzzi JL Jr.

Arch Cardiovasc Dis. 2012 Jan;105(1):40-50. doi: 10.1016/j.acvd.2011.10.007. Epub 2012 Jan 16. Review.

12.

Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial.

Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, Richards M, Sharpe N.

J Am Coll Cardiol. 2003 Nov 19;42(10):1793-800.

13.

Prognostic value of brain natriuretic peptide in noncardiac surgery: a meta-analysis.

Ryding AD, Kumar S, Worthington AM, Burgess D.

Anesthesiology. 2009 Aug;111(2):311-9. doi: 10.1097/ALN.0b013e3181aaeb11. Review.

PMID:
19602961
14.

Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers.

George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, Sheps D, Keren G.

Arch Intern Med. 2005 Jun 13;165(11):1304-9.

PMID:
15956012
15.

Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.

Manzano-Fernández S, Boronat-Garcia M, Albaladejo-Otón MD, Pastor P, Garrido IP, Pastor-Pérez FJ, Martínez-Hernández P, Valdés M, Pascual-Figal DA.

Am J Cardiol. 2009 Jun 15;103(12):1753-9. doi: 10.1016/j.amjcard.2009.02.029.

PMID:
19539088
16.

Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management.

Singer AJ, Birkhahn RH, Guss D, Chandra A, Miller CD, Tiffany B, Levy P, Dunne R, Bastani A, Thode HC Jr, Hollander JE.

Circ Heart Fail. 2009 Jul;2(4):287-93. doi: 10.1161/CIRCHEARTFAILURE.108.826685. Epub 2009 May 19.

17.

Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy.

Neuhold S, Huelsmann M, Strunk G, Struck J, Adlbrecht C, Gouya G, Elhenicky M, Pacher R.

Clin Chem. 2010 Jan;56(1):121-6. doi: 10.1373/clinchem.2009.125856. Epub 2009 Nov 2.

18.

Serial monitoring of brain natriuretic peptide concentrations for drug therapy management in patients with chronic heart failure.

Gallegos PJ, Maclaughlin EJ, Haase KK.

Pharmacotherapy. 2008 Mar;28(3):343-55. doi: 10.1592/phco.28.3.343. Review.

PMID:
18294114
19.

B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials.

Li P, Luo Y, Chen YM.

Heart Lung Circ. 2013 Oct;22(10):852-60. doi: 10.1016/j.hlc.2013.03.077. Epub 2013 Apr 17. Review.

PMID:
23602555
20.

Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies.

Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS.

Clin Cardiol. 2007 May;30(5):245-50.

Supplemental Content

Support Center